Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.60 |
| ▸ | USP5 | P45974 | 1/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10202699 | 0.93 | MAPT (0.62) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL879572 | 0.89 | ALDH1A1 (0.59) | SMN1; SMN2USP5FFAR1ALDH1A1L3MBTL1 | |
| SCHEMBL11390077 | 0.87 | ALDH1A1 (0.50) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL29009977 | 0.86 | HSD17B10 (0.57) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL14672780 | 0.85 | ALDH1A1 (0.49) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL15177360 | 0.85 | ALDH1A1 (0.49) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL6208836 | 0.84 | SMN1; SMN2 (0.82) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL25946094 | 0.84 | ALDH1A1 (0.48) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL443048 | 0.83 | ALDH1A1 (0.48) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A | |
| SCHEMBL8986797 | 0.83 | HSD17B10 (0.54) | HSD17B10SMN1; SMN2HDAC3MAPK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | claimed |
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | NOVO NORDISK A/S (DK) | 2020-12-31 | — | — | US | claimed |
| EP-2114145-B1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECH INC (US) | 2017-11-01 | — | — | EP | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| CN-105233294-A | Phenylalkylcarboxylic acid delivery agent | EMISPHERE TECH INC | 2016-01-13 | — | — | CN | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20120258911-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-10-11 | — | — | US | claimed |
| US-20110046050-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-02-24 | — | — | US | claimed |
| CN-101616583-A | Phenylalkylcarboxylic acid delivery agents | EMISPHERE TECH INC | 2009-12-30 | — | — | CN | claimed |
| EP-2114145-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | Emisphere Technologies, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008112368-A2 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2022-02-22 | — | — | US | disclosed |
| CN-1151744-A | Phosphonic acid compounds, their prodn. and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-06-11 | — | — | CN | disclosed |
| EP-0769015-A1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001267-A1 | PHOSPHONIC ACID COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405863-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | HSD17B10 1647/4885SMN1; SMN2 2780/4885HDAC3 487/4885 |
| US-20110046050-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | HSD17B10 1647/4885SMN1; SMN2 2780/4885HDAC3 487/4885 |
| US-11253596-B2 | Phenylalkylcarboxylic acid delivery agents | PGF, LIPA, PDGFA | HSD17B10 1647/4885SMN1; SMN2 2780/4885HDAC3 487/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | HSD17B10 1827/4885SMN1; SMN2 366/4885HDAC3 2064/4885 |
| US-20120258911-A1 | PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS | PGF, LIPA, PDGFA | HSD17B10 1647/4885SMN1; SMN2 2780/4885HDAC3 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.